A Clinical Trial Evaluating the Safety and Efficacy of ABX-EGF in Patients With Hormone Resistant Prostate Cancer With or Without Metastasis
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
United States: Food and Drug Administration
ABX-0310
NCT00061126
April 2003
Name | Location |
---|---|
UCLA School of Medicine | Los Angeles, California 900121973 |
Fox Chase Cancer Center | Philadelphia, Pennsylvania 19111 |
Madigan Army Medical Center | Tacoma, Washington 98431-5048 |
Urology San Antonio Research | San Antonio, Texas 78229 |
University of Washington | Seattle, Washington 98195 |
University of Alabama at Birmingham | Birmingham, Alabama 35294-3300 |
Advanced Research Institute | New Port Richey, Florida 34652 |
Stanford Medical Center | Stanford, California 94303 |
University of Pittsburgh Cancer Institute, Hillman Cancer Center | Pittsburgh, Pennsylvania 15232 |